{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:26:28Z","timestamp":1783347988089,"version":"3.54.6"},"reference-count":27,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006190","name":"National Major Research and Development Program of China","doi-asserted-by":"publisher","award":["2017YFC1200902"],"award-info":[{"award-number":["2017YFC1200902"]}],"id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.vaccine.2020.02.060","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T08:29:56Z","timestamp":1582705796000},"page":"2978-2983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A"],"prefix":"10.1016","volume":"38","author":[{"given":"Fu-Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Yang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Yun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Hua","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Sheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Bin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Xin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Zhou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.02.060_b0005","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.toxicon.2013.01.017","article-title":"Botulinum neurotoxins","volume":"67","author":"Rossetto","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.vaccine.2020.02.060_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/toxins9010038","article-title":"Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature","volume":"9","author":"Peck","year":"2017","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2020.02.060_b0015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.resmic.2014.09.007","article-title":"Historical and current perspectives on Clostridium botulinum diversity","volume":"166","author":"Smith","year":"2015","journal-title":"Res Microbiol"},{"key":"10.1016\/j.vaccine.2020.02.060_b0020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/protein\/gzq111","article-title":"Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin","volume":"24","author":"Garcia-Rodriguez","year":"2011","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.vaccine.2020.02.060_b0025","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-3-319-72077-7_9","article-title":"Therapeutic antibodies for biodefense","volume":"1053","author":"Avril","year":"2017","journal-title":"AAdv Exp Med Biol"},{"key":"10.1016\/j.vaccine.2020.02.060_b0030","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s11095-015-1816-x","article-title":"In vivo toxicity and immunological characterization of detoxified recombinant botulinum neurotoxin type A","volume":"33","author":"Ravichandran","year":"2016","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2020.02.060_b0035","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/2338","article-title":"Crystal structure of botulinum neurotoxin type A and implications for toxicity","volume":"5","author":"Lacy","year":"1998","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.vaccine.2020.02.060_b0040","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.vaccine.2020.02.060_b0045","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1111\/j.1742-4658.2011.08183.x","article-title":"Molecular structures and functional relationships in clostridial neurotoxins","volume":"278","author":"Swaminathan","year":"2011","journal-title":"FEBS J"},{"key":"10.1016\/j.vaccine.2020.02.060_b0050","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jmb.2006.09.084","article-title":"Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display","volume":"365","author":"Levy","year":"2007","journal-title":"J Mol Biol"},{"key":"10.1016\/j.vaccine.2020.02.060_b0055","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1017\/S0033583500003292","article-title":"Structure and function of tetanus and botulinum neurotoxins","volume":"28","author":"Montecucco","year":"1995","journal-title":"Q Rev Biophys"},{"key":"10.1016\/j.vaccine.2020.02.060_b0060","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.vaccine.2017.12.064","article-title":"Enhancing toxin-based vaccines against botulism","volume":"36","author":"Przedpelski","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.060_b0065","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1128\/IAI.00405-09","article-title":"Antibody protection against botulinum neurotoxin intoxication in mice","volume":"77","author":"Cheng","year":"2009","journal-title":"Infect Immun"},{"issue":"Suppl 8","key":"10.1016\/j.vaccine.2020.02.060_b0070","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1002\/mds.20020","article-title":"Basic immunological aspects of botulinum toxin therapy","volume":"19","author":"Atassi","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.vaccine.2020.02.060_b0075","first-page":"39","article-title":"Uptake of clostridial neurotoxins into cells and dissemination","volume":"406","author":"Connan","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2020.02.060_b0080","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.mib.2012.05.009","article-title":"Vaccines against botulism","volume":"15","author":"Karalewitz","year":"2012","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.vaccine.2020.02.060_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/toxins9090268","article-title":"Vaccines against Botulism","volume":"9","author":"Sundeen","year":"2017","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2020.02.060_b0090","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/21645515.2018.1547613","article-title":"Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B","volume":"15","author":"Shi","year":"2019","journal-title":"Human Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2020.02.060_b0095","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/21645515.2017.1405201","article-title":"A mutated recombinant subunit vaccine protects mice and guinea pigs against botulinum type A intoxication","volume":"14","author":"Yu","year":"2018","journal-title":"Human Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2020.02.060_b0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.vaccine.2017.11.008","article-title":"Dual-route targeted vaccine protects efficiently against botulinum neurotoxin A complex","volume":"36","author":"Sahay","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.060_b0105","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.anaerobe.2014.06.003","article-title":"Production of recombinant botulism antigens: a review of expression systems","volume":"28","author":"Moreira","year":"2014","journal-title":"Anaerobe"},{"key":"10.1016\/j.vaccine.2020.02.060_b0110","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/erv.13.37","article-title":"What next for botulism vaccine development?","volume":"12","author":"Webb","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.vaccine.2020.02.060_b0115","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.vaccine.2009.02.091","article-title":"The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate","volume":"27","author":"Yu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.060_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10020084","article-title":"A single tri-epitopic antibody virtually recapitulates the potency of a combination of three monoclonal antibodies in neutralization of botulinum neurotoxin serotype A","volume":"10","author":"Lou","year":"2018","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2020.02.060_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/toxins9090269","article-title":"Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism","volume":"9","author":"Webb","year":"2017","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2020.02.060_b0130","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.vaccine.2018.02.042","article-title":"Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A\/B, in volunteers with pre-existing botulinum toxoid immunity","volume":"36","author":"Khouri","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.060_b0135","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.1016\/j.vaccine.2010.08.076","article-title":"Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A\/B)","volume":"28","author":"Shearer","year":"2010","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20302838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20302838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:42:37Z","timestamp":1759401757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20302838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":27,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0264410X20302838"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.060","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}